77 results on '"Ghanima, Waleed"'
Search Results
2. Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy
3. Physical activity following pulmonary embolism and clinical correlates in selected patients: a cross-sectional study
4. Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
5. Evaluation of the diagnostic performance of three D-dimer assays in patients with suspected deep vein thrombosis: STA-Liatest D-Di plus, Tina-quant D-dimer Gen. 2, and INNOVANCE D-dimer
6. Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
7. The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial
8. Demographic, clinical, and echocardiographic factors associated with residual perfusion defects beyond six months after pulmonary embolism
9. Arterial events in cancer patients treated with apixaban for venous thrombosis
10. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial
11. Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry
12. SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people
13. The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description
14. Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
15. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow‐up
16. Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients
17. Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
18. Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
19. Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology
20. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns
21. Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
22. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study
23. Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis
24. Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
25. Risk factors for symptomatic venous thromboembolism following surgery for closed ankle fractures: A case-control study
26. Gastric sleeve resection as day-case surgery: what affects the discharge time?
27. Updated international consensus report on the investigation and management of primary immune thrombocytopenia
28. Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim
29. Pain and nausea after bariatric surgery with total intravenous anesthesia versus desflurane anesthesia: a double blind, randomized, controlled trial
30. Cardiovascular and bleeding outcomes in a population‐based cohort of patients with chronic immune thrombocytopenia
31. Corrigendum to “Evaluation of the diagnostic performance of three D-dimer assays in patients with suspected deep vein thrombosis: STA-Liatest D-Di Plus, Tina-quant D-Dimer Gen. 2, and INNOVANCE D-Dimer” [Thrombosis Update, 13(2023) 100147]
32. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial
33. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
34. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
35. Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study
36. “Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients ‐ 30 months follow‐up”: Reply
37. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
38. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities
39. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
40. Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility
41. An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination
42. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions
43. A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)
44. Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag
45. The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0
46. Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia
47. Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders
48. Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry
49. Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)
50. Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.